Legacy plans for lyophilisation boom

14 May 2019

The increase in biologics is driving the growth in demand for lyophilization in vials.

Legacy Pharmaceuticals, a global contract manufacturer of sterile/aseptic pharmaceutical products in ampoules and vials, has announced their long-term expansion strategy to address the global growth in demand for lyophilization in vials.

Legacy plans for lyophilisation boom

The 5-year plan builds on Legacy’s existing core fill finish competencies in lyophilization, and liquid and powder vials. As a first step Legacy has already started a project to add customized lyophilization in vials for an ongoing customer project, with an anticipated start date of mid-2020.

Lyophilization in vials is a trend in the industry that continues to grow due to the increase of biologicals. Already the share of injectable/infusible lyophilized drugs approved has risen from 11.9% in 1999 to over 50% and is still predicted to increase. Main product types include cell and cell-based therapies, small molecule drugs, diagnostics and biologics, including peptides, recombinant proteins and vaccines.

“By 2020, global pharma companies estimate lyophilized drugs will represent 30-40% of their pipeline. However, the manufacturing capacity our industry needs does not exist at the moment, and it cannot be built overnight. Decisions need to be taken now, which is why we are announcing this expansion strategy and committing to increasing our capacity. Legacy is planning to build a lyophilization suite with closed RABS filling line technology, two to three freeze dryers up to 30-m2 scale each and automated load and unloading systems. We estimate a construction timeframe in the order of 24-30 months. We are now looking to open discussions with existing and new customers interested to retain capacity in this strategic project,“ commented Mike Danzi, CEO of Legacy Pharmaceuticals.

Read More

Related news

Improving gut health with human milk oligosaccharides

Improving gut health with human milk oligosaccharides

17 May 2019

2’-FL a very promising agent for digestive health across various age groups beyond infancy.

Read more 
Expert forecasts huge growth in Middle East manufacturing

Expert forecasts huge growth in Middle East manufacturing

16 May 2019

UAE consumers and insurance companies are willing to pay for highest quality drug products.

Read more 
Colorcon's breakthrough for direct compression

Colorcon's breakthrough for direct compression

15 May 2019

New starch-based excipient plays an important role in enhancing the stability of moisture-sensitive APIs.

Read more 
Lessons learned from early EU FMD adopters

Lessons learned from early EU FMD adopters

13 May 2019

Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.

Read more 
Catalent achieves global ISO accreditation

Catalent achieves global ISO accreditation

12 May 2019

Company is one of the first CDMOs to receive award.

Read more 
Vibalogics increases capacity with a new 200-L line for virus manufacturing

Vibalogics increases capacity with a new 200-L line for virus manufacturing

9 May 2019

Company has also invested in an Äkta-ready chromatography system for downstream processing and liquid handling equipment to deal with increased volumes.

Read more 
New SIMCA 16 software for multivariate data analytics

New SIMCA 16 software for multivariate data analytics

8 May 2019

Makes model data easier to interpret for better process control.

Read more 
Recipharm launches its end-to-end inhalation offering

Recipharm launches its end-to-end inhalation offering

7 May 2019

Offers a seamless outsourcing service for inhalation products, including MDIs, DPIs and nasal sprays.

Read more 
Accessible online courses designed to improve tablet compression tooling

Accessible online courses designed to improve tablet compression tooling

7 May 2019

I Holland launches online training for all levels of pharmaceutical and nutraceutical professionals.

Read more 
WuXi AppTec acquisition enhances its biometrics services for clinical development

WuXi AppTec acquisition enhances its biometrics services for clinical development

6 May 2019

Acquisition will help customers to shorten time-to-market of new drugs.

Read more